These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 20626400)

  • 1. The antianginal agent ranolazine is a potent antiarrhythmic agent that reduces ventricular arrhythmias: through a mechanism favoring inhibition of late sodium channel.
    Kloner RA; Dow JS; Bhandari A
    Cardiovasc Ther; 2011 Aug; 29(4):e36-41. PubMed ID: 20626400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ranolazine, an antianginal agent, markedly reduces ventricular arrhythmias induced by ischemia and ischemia-reperfusion.
    Dhalla AK; Wang WQ; Dow J; Shryock JC; Belardinelli L; Bhandari A; Kloner RA
    Am J Physiol Heart Circ Physiol; 2009 Nov; 297(5):H1923-9. PubMed ID: 19767532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First direct comparison of the late sodium current blocker ranolazine to established antiarrhythmic agents in an ischemia/reperfusion model.
    Kloner RA; Dow JS; Bhandari A
    J Cardiovasc Pharmacol Ther; 2011 Jun; 16(2):192-6. PubMed ID: 21193683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ranolazine, an inhibitor of the late sodium channel current, reduces postischemic myocardial dysfunction in the rabbit.
    Hale SL; Kloner RA
    J Cardiovasc Pharmacol Ther; 2006 Dec; 11(4):249-55. PubMed ID: 17220471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved left ventricular function and reduced necrosis after myocardial ischemia/reperfusion in rabbits treated with ranolazine, an inhibitor of the late sodium channel.
    Hale SL; Leeka JA; Kloner RA
    J Pharmacol Exp Ther; 2006 Jul; 318(1):418-23. PubMed ID: 16617168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiarrhythmic effect of ischemic preconditioning during low-flow ischemia. The role of bradykinin and sarcolemmal versus mitochondrial ATP-sensitive K(+) channels.
    Driamov S; Bellahcene M; Ziegler A; Barbosa V; Traub D; Butz S; Buser PT; Zaugg CE
    Basic Res Cardiol; 2004 Jul; 99(4):299-308. PubMed ID: 15221348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ranolazine: an antianginal drug with antiarrhythmic properties.
    Tamargo J; Caballero R; Delpón E
    Expert Rev Cardiovasc Ther; 2011 Jul; 9(7):815-27. PubMed ID: 21809962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A focus on antiarrhythmic properties of ranolazine.
    Vizzardi E; D'Aloia A; Quinzani F; Bonadei I; Rovetta R; Bontempi L; Curnis A; Dei Cas L
    J Cardiovasc Pharmacol Ther; 2012 Dec; 17(4):353-6. PubMed ID: 22492919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ranolazine as a cardioplegia additive improves recovery of diastolic function in isolated rat hearts.
    Hwang H; Arcidi JM; Hale SL; Simkhovich BZ; Belardinelli L; Dhalla AK; Shryock JC; Kloner RA
    Circulation; 2009 Sep; 120(11 Suppl):S16-21. PubMed ID: 19752362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel, potent, and selective inhibitor of cardiac late sodium current suppresses experimental arrhythmias.
    Belardinelli L; Liu G; Smith-Maxwell C; Wang WQ; El-Bizri N; Hirakawa R; Karpinski S; Li CH; Hu L; Li XJ; Crumb W; Wu L; Koltun D; Zablocki J; Yao L; Dhalla AK; Rajamani S; Shryock JC
    J Pharmacol Exp Ther; 2013 Jan; 344(1):23-32. PubMed ID: 23010360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Noradrenaline reduces ischemia-induced arrhythmia in anesthetized rats: involvement of alpha1-adrenoceptors and mitochondrial K ATP channels.
    Imani A; Faghihi M; Sadr SS; Keshavarz M; Niaraki SS
    J Cardiovasc Electrophysiol; 2008 Mar; 19(3):309-15. PubMed ID: 18070031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiarrhythmic effect of caffeic acid phenethyl ester (CAPE) on myocardial ischemia/reperfusion injury in rats.
    Huang SS; Liu SM; Lin SM; Liao PH; Lin RH; Chen YC; Chih CL; Tsai SK
    Clin Biochem; 2005 Oct; 38(10):943-7. PubMed ID: 16098504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The potential antiarrhythmic effects of exogenous and endogenous bradykinin in the ischaemic rat heart in vivo.
    Sun W; Wainwright CL
    Coron Artery Dis; 1994 Jun; 5(6):541-50. PubMed ID: 7952414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effects of Shen-song-yang-xin capsule on ventricular arrhythmias in ischemia/reperfusion: experiment with rats].
    Ren JY; Li LJ; Wang RJ; Chen H; Wu YL; Luo Y
    Zhonghua Yi Xue Za Zhi; 2008 Dec; 88(48):3440-3. PubMed ID: 19159580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiarrhythmic effects of ranolazine in a guinea pig in vitro model of long-QT syndrome.
    Wu L; Shryock JC; Song Y; Li Y; Antzelevitch C; Belardinelli L
    J Pharmacol Exp Ther; 2004 Aug; 310(2):599-605. PubMed ID: 15031300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiarrhythmic properties of ranolazine--from bench to bedside.
    Tzeis S; Andrikopoulos G
    Expert Opin Investig Drugs; 2012 Nov; 21(11):1733-41. PubMed ID: 22916846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The late Na+ current (INa) inhibitor ranolazine attenuates effects of palmitoyl-L-carnitine to increase late INa and cause ventricular diastolic dysfunction.
    Wu Y; Song Y; Belardinelli L; Shryock JC
    J Pharmacol Exp Ther; 2009 Aug; 330(2):550-7. PubMed ID: 19403851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of acute versus delayed remote ischemic preconditioning on reperfusion induced ventricular arrhythmias.
    Dow J; Bhandari A; Simkhovich BZ; Hale SL; Kloner RA
    J Cardiovasc Electrophysiol; 2012 Dec; 23(12):1374-83. PubMed ID: 23134527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Late sodium current inhibition alone with ranolazine is sufficient to reduce ischemia- and cardiac glycoside-induced calcium overload and contractile dysfunction mediated by reverse-mode sodium/calcium exchange.
    Soliman D; Wang L; Hamming KS; Yang W; Fatehi M; Carter CC; Clanachan AS; Light PE
    J Pharmacol Exp Ther; 2012 Nov; 343(2):325-32. PubMed ID: 22879384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Class I/B antiarrhythmic property of ranolazine, a novel antianginal agent, in dog and human cardiac preparations.
    Szél T; Koncz I; Jost N; Baczkó I; Husti Z; Virág L; Bussek A; Wettwer E; Ravens U; Papp JG; Varró A
    Eur J Pharmacol; 2011 Jul; 662(1-3):31-9. PubMed ID: 21550338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.